Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial

Paolo Cassano, Samuel R. Petrie, David Mischoulon, Cristina Cusin, Husam Katnani, Albert Yeung, Luis De Taboada, Abigal Archibald, Eric Bui, Lee Baer, Trina Chang, Justin Chen, Paola Pedrelli, Lauren Fisher, Amy Farabaugh, Michael R. Hamblin, Jonathan E. Alpert, Maurizio Fava, Dan V. Iosifescu

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.

Original languageEnglish (US)
Pages (from-to)634-646
Number of pages13
JournalPhotomedicine and Laser Surgery
Volume36
Issue number12
DOIs
StatePublished - Dec 1 2018
Externally publishedYes

Fingerprint

Major Depressive Disorder
Observation
Antidepressive Agents
Infrared radiation
Light
Neuronal Plasticity
Prefrontal Cortex
Mitochondria
Oxidative stress
Sample Size
Opioid Analgesics
Oxidative Stress
Metabolism
Depression
Inflammation
Safety
phytobacteriomycin
Therapeutics

Keywords

  • depression
  • low-level laser therapy
  • randomized controlled trial

ASJC Scopus subject areas

  • Biomedical Engineering
  • Radiology Nuclear Medicine and imaging

Cite this

Cassano, P., Petrie, S. R., Mischoulon, D., Cusin, C., Katnani, H., Yeung, A., ... Iosifescu, D. V. (2018). Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial. Photomedicine and Laser Surgery, 36(12), 634-646. https://doi.org/10.1089/pho.2018.4490

Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial. / Cassano, Paolo; Petrie, Samuel R.; Mischoulon, David; Cusin, Cristina; Katnani, Husam; Yeung, Albert; De Taboada, Luis; Archibald, Abigal; Bui, Eric; Baer, Lee; Chang, Trina; Chen, Justin; Pedrelli, Paola; Fisher, Lauren; Farabaugh, Amy; Hamblin, Michael R.; Alpert, Jonathan E.; Fava, Maurizio; Iosifescu, Dan V.

In: Photomedicine and Laser Surgery, Vol. 36, No. 12, 01.12.2018, p. 634-646.

Research output: Contribution to journalArticle

Cassano, P, Petrie, SR, Mischoulon, D, Cusin, C, Katnani, H, Yeung, A, De Taboada, L, Archibald, A, Bui, E, Baer, L, Chang, T, Chen, J, Pedrelli, P, Fisher, L, Farabaugh, A, Hamblin, MR, Alpert, JE, Fava, M & Iosifescu, DV 2018, 'Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial', Photomedicine and Laser Surgery, vol. 36, no. 12, pp. 634-646. https://doi.org/10.1089/pho.2018.4490
Cassano, Paolo ; Petrie, Samuel R. ; Mischoulon, David ; Cusin, Cristina ; Katnani, Husam ; Yeung, Albert ; De Taboada, Luis ; Archibald, Abigal ; Bui, Eric ; Baer, Lee ; Chang, Trina ; Chen, Justin ; Pedrelli, Paola ; Fisher, Lauren ; Farabaugh, Amy ; Hamblin, Michael R. ; Alpert, Jonathan E. ; Fava, Maurizio ; Iosifescu, Dan V. / Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial. In: Photomedicine and Laser Surgery. 2018 ; Vol. 36, No. 12. pp. 634-646.
@article{163c941c926f4a9188e930305ca72aea,
title = "Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial",
abstract = "Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.",
keywords = "depression, low-level laser therapy, randomized controlled trial",
author = "Paolo Cassano and Petrie, {Samuel R.} and David Mischoulon and Cristina Cusin and Husam Katnani and Albert Yeung and {De Taboada}, Luis and Abigal Archibald and Eric Bui and Lee Baer and Trina Chang and Justin Chen and Paola Pedrelli and Lauren Fisher and Amy Farabaugh and Hamblin, {Michael R.} and Alpert, {Jonathan E.} and Maurizio Fava and Iosifescu, {Dan V.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1089/pho.2018.4490",
language = "English (US)",
volume = "36",
pages = "634--646",
journal = "Photomedicine and Laser Surgery",
issn = "1549-5418",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Transcranial Photobiomodulation for the Treatment of Major Depressive Disorder. the ELATED-2 Pilot Trial

AU - Cassano, Paolo

AU - Petrie, Samuel R.

AU - Mischoulon, David

AU - Cusin, Cristina

AU - Katnani, Husam

AU - Yeung, Albert

AU - De Taboada, Luis

AU - Archibald, Abigal

AU - Bui, Eric

AU - Baer, Lee

AU - Chang, Trina

AU - Chen, Justin

AU - Pedrelli, Paola

AU - Fisher, Lauren

AU - Farabaugh, Amy

AU - Hamblin, Michael R.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

AU - Iosifescu, Dan V.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.

AB - Objective: Our objective was to test the antidepressant effect of transcranial photobiomodulation (t-PBM) with near-infrared (NIR) light in subjects suffering from major depressive disorder (MDD). Background: T-PBM with NIR light is a new treatment for MDD. NIR light is absorbed by mitochondria; it boosts cerebral metabolism, promotes neuroplasticity, and modulates endogenous opioids, while decreasing inflammation and oxidative stress. Materials and methods: We conducted a double-blind, sham-controlled study on the safety and efficacy [change in Hamilton Depression Rating Scale (HAM-D17) total score at end-point] of adjunct t-PBM NIR [823 nm; continuous wave (CW); 28.7 × 2 cm2; 36.2 mW/cm2; up to 65.2 J/cm2; 20-30 min/session], delivered to dorsolateral prefrontal cortex, bilaterally and simultaneously, twice a week, for 8 weeks, in subjects with MDD. Baseline observation carried forward (BOCF), last observation carried forward (LOCF), and completers analyses were performed. Results: The effect size for the antidepressant effect of t-PBM, based on change in HAM-D17 total score at end-point, was 0.90, 0.75, and 1.5 (Cohen's d), respectively for BOCF (n = 21), LOCF (n = 19), and completers (n = 13). Further, t-PBM was fairly well tolerated, with no serious adverse events. Conclusions: T-PBM with NIR light demonstrated antidepressant properties with a medium to large effect size in patients with MDD. Replication is warranted, especially in consideration of the small sample size.

KW - depression

KW - low-level laser therapy

KW - randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=85053529628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053529628&partnerID=8YFLogxK

U2 - 10.1089/pho.2018.4490

DO - 10.1089/pho.2018.4490

M3 - Article

VL - 36

SP - 634

EP - 646

JO - Photomedicine and Laser Surgery

JF - Photomedicine and Laser Surgery

SN - 1549-5418

IS - 12

ER -